<a href="https://laohu8.com/S/AWH">Aspira Women's Health Inc.</a> Partners with Dorsata to Launch Adnexal Mass Clinical Tool, Expanding Access to 1.5 Million Patients Across 300+ Practices
Aspira Women's Health Inc. has announced a new collaboration with Dorsata to launch a clinical decision support module for adnexal masses. This partnership aims to modernize women's healthcare by integrating tech-enabled clinical tools to facilitate early detection and precision diagnostics. The new module is now available to over 700 women's health providers at more than 300 practice sites across 20 states, impacting the care of over 1.5 million patients annually. This initiative aligns with Aspira's strategy to expand the adoption of its Ova1Plus® and OvaWatch® products efficiently. Aspira CEO Mike Buhle expressed pride in this milestone, highlighting its significance in enhancing value for providers, patients, and the company.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspira Women's Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1040229) on June 17, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。